T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Clinical trial NCT03049449 · COMPLETED

Trial details

NCT number: NCT03049449
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Large-Cell, Anaplastic Enteropathy-Associated T-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Extranodal NK-T-Cell Lymphoma, T-Cell, Peripheral

Start date: 2017-03-17
Primary completion: 2022-01-26
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.